FDA Takes More Conservative Approach To Quantifying Oncologic Benefit
Executive Summary
FDA seems to be taking a more conservative approach to quantifying oncologics' benefits, based on agency comments during a Sept. 13-14 meeting of its Oncologic Drugs Advisory Committee
You may also be interested in...
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005